BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
More about this company
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Sector: health
Conviction from: NASDAQ
52-week range: 17.8639.76
3 tracked filer(s) hold this · 3 opened, 0 added, 0 trimmed in 30-SEP-2026
Aggregate 13FScore 50 — mean of 3 scored holder(s) · buyers (new/add) avg 50. Higher = the smart money in this name has the better track record.
Beyond 13F — activists, insiders, politicians & research
2 disclosed trade(s) by 1 filer(s).